Blood plasma, taking up 55% of total blood volume, is the most significant and major component of blood. For that reason, blood plasma is hugely valuable in treating chronic conditions, and is an integral component of biotechnology.
With the BIO 2023 event fast approaching, BCC Research is ascertaining the lay of the land across the sector. BCC Research expects the global market for blood plasma products to grow at a compound annual growth rate (CAGR) of 6.6% to reach $45.7 billion by 2027. The increasing demand for immunoglobulins in various therapies, the rising prevalence of Alpha-1 Antitrypsin Deficiency (AATD) and the increase in blood donations are the key drivers of this.
Momentum for blood plasma products is mounting. Let’s dive into the top 10 companies in the market.
Leading players in the blood plasma products market
Technological advancements and improvements in blood plasma fractionation technologies have revolutionized the market. While small players operate regionally, the Market for Blood Plasma Products is mostly consolidated by the domination of large global companies.
1. CSL Behring
CSL is an international company that specializes in manufacturing biotherapeutic products. Their innovative biotherapeutic products offer safe treatments to people suffering from chronic medical conditions. The company has a significant geographical presence in Australia, Germany, Switzerland, China, the UK and the US, and employs roughly 25,000 people in over 35 countries.
With nearly 33% of the total, CSL Behring held the highest market share in 2021. The company operates over 300 plasma collection centers and is focused on boosting its R&D capabilities.
The second leading company in blood plasma products is Takeda, a pharmaceutical company that manufactures treatments, vaccines and therapies for various diseases. The company has over 75 years of experience in producing plasma-derived therapies for various rare diseases and operates through over 200 collection centers globally. With a market share of 29.5% in 2021, the company moves from strength to strength.
Grifols SA manufactures and supplies protein therapies for patients and provides medical care tools to hospitals, pharmacies and other healthcare professionals. The company was founded in 1940 in Barcelona, Spain. The three prime divisions of the company are bioscience, diagnostic and hospital. The company’s plasma-based products are included in the bioscience segment. The company provides innovative products and services to medical professionals in more than 90 countries. Grifols is a leading manufacturer of plasma-derived therapies, essentially used in treating patients suffering from rare genetic diseases or severe infections.
Grifols captured the third position with a market share of 12.8% in 2021. Running nearly 366 plasma collection centers, the company focuses on improving its plasma collection capacity through facility expansions and acquisitions. Grifols engages in private and private-public models for operating its plasma donation centers.
Number four on the list is Swiss company Octapharma. The company is involved in manufacturing therapeutic proteins, operating in hematology, immunohematology and critical care. It’s considered one of the largest manufacturers of human proteins.
With a market share of 8.3% in 2021, Octapharma manages over 180 plasma collection centers with a strong hematology, immunology and critical care portfolio. The company has five manufacturing sites and seven pre-clinical and clinical R&D facilities, and an employee strength of nearly 9,977 people.
Kedrion is the fifth leading company. It collects and fractionates human plasma to manufacture therapeutic plasma products used to treat chronic diseases such as hemophilia, leukemia, Rh sensitization and immunodeficiencies. The company, founded in 2001, works in partnership with the Italian National Health System to meet the demand for plasma-derived products.
Kedrion accounted for a 2.3% market share in 2021. Kedrion strives to develop innovative plasma products to strengthen its product portfolio, and the company’s R&D is its backbone for developing innovative immunoglobulin therapies. The company operates through 29 plasma collection centers.
6. LFB SA
The LFB group are experts in manufacturing, developing and marketing the biological medicines used to treat rare diseases. The group, a significant player in European biopharmaceuticals, manufactures products that are primarily utilized by hospital-based health professionals. The company has established different bioproduction techniques through which it offers plasma-derived medicinal products. The LFB group was founded in 1994 and operates through three segments: immunology, hemostasis and intensive care. LFB manufactures over 15 products available in 30+ countries.
ADMA manufactures products used in immune technology. The company strives to develop therapies that treat infection in immunodeficient patients. Through its ADMA BioCenters subsidiary, the company operates FDA-licensed source plasma collection facilities in the US.
The company’s key customers include BioCARE Inc., Reliance Life Sciences Pvt. Limited, AmerisourceBergen Corporation and Priority Healthcare Distribution Inc., which combined represented 81% of the revenues in 2021.
8. China Biologic Products
China Biologic Products is the leading biopharmaceutical company in China, manufacturing plasma-based products. The company has achieved expertise in R&D, plasma collection and the commercialization of biopharmaceutical products.
9. Bio Products Laboratory
Bio Products Laboratory (BPL) produces a range of human plasma-derived medicines to treat immune deficiencies, blood disorders, critical care and infectious diseases. The company’s therapeutic products are commercially available in over 50 countries.
Sanquin works on a nonprofit basis to offer a safe and steady supply of blood and blood plasma products in the Netherlands. The company also manufactures pharmaceutical products and focuses on R&D and diagnostic services. Sanquin is the only source of blood and blood components in the Netherlands, currently employing approximately 3,000 people throughout the country.
Unlock the market dynamics for blood plasma products
BCC Research’s report on blood plasma products analyses the market opportunities and provides five-year forecasting to help you stay ahead of the curve. Download your complimentary overview here.
You can also sign up to receive our BIO 2023 post-show report, to gain insight across the biotechnology landscape.